PADMA 28

SCIENTIFIC DOCUMENTATION

- Abstracts of selected articles
- Detailed list of publications

09 / 2010

This index is for medical professionals.
**Content:**

<table>
<thead>
<tr>
<th>Subject:</th>
<th>Authors, titles</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>PAOD:</td>
<td>Melzer J, Brignoli R, Diehm C, Reichling J, Do DD, Saller R</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Treating intermittent claudication with Tibetan medicine Padma 28: Does it work?</td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus:</td>
<td>von Muralt Portmann</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Paresthesias in diabetes mellitus – Treatment approaches with PADMA 28</td>
<td></td>
</tr>
<tr>
<td>Hepatitis:</td>
<td>Brzosko WJ, Jankowski A</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>PADMA 28 in patients with chronic hepatitis B: Clinical and immunological effects</td>
<td></td>
</tr>
<tr>
<td>MS:</td>
<td>Korwin-Piotrowska T, Nocon D, Stankowska-Chomicz A, Starkiewicz A, Wojcicki J,</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Samochowiec L</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Experience of PADMA 28 in Multiple Sclerosis</td>
<td></td>
</tr>
<tr>
<td>Immune defence:</td>
<td>Jankowski A, Jankowska R, Brzosko WJ</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Treatment of children prone to infection with PADMA 28</td>
<td></td>
</tr>
<tr>
<td>Cardiology:</td>
<td>Literature</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>PADMA 28 in cardiology: the role of regulatory systems in inflammatory heart diseases</td>
<td></td>
</tr>
<tr>
<td>Dental pulpitis:</td>
<td>Füllemann F</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Padma 28 in the treatment of chronic dental pulpitis: an observational case study in 49 patients</td>
<td></td>
</tr>
<tr>
<td>Clinical experiences:</td>
<td>Bommeli C, Bohnsack R, Kolb C</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Clinical experiences in the general practice with a multicompound preparation derived from Tibetan medicine</td>
<td></td>
</tr>
<tr>
<td>Review:</td>
<td>Anonymous</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>Arteriosclerosis, restenosis and tumor progression: PADMA 28 has antiproliferative effects on activated smooth-muscle cells and tumor cells.</td>
<td></td>
</tr>
<tr>
<td>Inflammaging:</td>
<td>Ginsburg I, Vennos C, Koren E</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>Inflammaging - Aging as a Consequence of Chronic Inflammation: The Example of Padma 28</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Schwabl H, Vennos C</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>Chronic Inflammation and Extracellular Matrix ECM: Starting Point for an Anti-Inflammatory Intervention Scheme</td>
<td></td>
</tr>
<tr>
<td>Tibetan medicine in Europe</td>
<td>Schwabl H, Vennos C</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>The “multi-target“ approach of Tibetan remedies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mechanisms of action of Padma 28 in inflammation, with the example of atherosclerosis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Anti-inflammatory mechanisms of the Tibetan herbal preparation Padma 28 in the vessel wall</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Barak V, Kalickman I, Halperin T, Birkenfeld S, Ginsburg I</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>PADMA 28, A Tibetan herbal preparation is an inhibitor of inflammatory cytokine production</td>
<td></td>
</tr>
</tbody>
</table>
Peripheral Arterial Occlusive Disease, PAOD
Melzer J, Brignoli R, Diehm C, Reichling J, Do DD, Saller R

Treating intermittent claudication with Tibetan medicine Padma 28: Does it work?


Herbal drugs are being increasingly used in medical practice, often without appropriate scrutiny of their safety and efficacy. The medicinal product Padma 28 is a fixed combination with Tibetan origin, used in Europe since the 1960s for the symptomatic treatment of circulatory disorders, including those of peripheral arterial occlusive disease (PAOD). We have conducted an analysis of all available data on this herbal drug from published literature as well as from original data we obtained from contacting the authors of published papers, reports and the manufacturer. A total of 19 trials have reported on 2084 patients to date, 444 of whom were in six controlled clinical studies on PAOD. A meta-analysis of five trials showed Padma 28 to increase walking distance by >100m in 18.2% of the patients with verum, versus 2.1% with placebo (P<0.001; odds ratio: 10 [95% CI 3.03, 33.33]; RR: 0.12; number needed to treat=6.2). The safety profile appears to be favourable. Available evidence shows that Padma 28 provides significant relief from PAOD-related symptoms (i.e. walking distance), probably of the same order of magnitude as other employed medications. However, larger confirmatory RCTs are desirable.

Diabetes mellitus
von Muralt Portmann

Paresthesias in diabetes mellitus – Treatment approaches with PADMA 28

Conclusions for general medical practice: The incidence of Type 2 diabetes mellitus is increasing and experts are already speaking of a “diabetes epidemic”. Due to the increasing proportion of patients with concomitant diseases and the increase in diabetes associated diseases, a comprehensive therapeutic approach on the part of general practitioners is necessary. Besides the adaptation of life-style factors, phytotherapeutic drugs which have anti-oxidant and anti-inflammatory properties and which thus act on the central pathogenic processes may also be used in the management of diabetes. The example of the use PADMA 28 in the treatment of diabetes-related paresthesias and pain shows that phytotherapeutics have a promising potential in the prevention and treatment of diabetes associated diseases.

Hepatitis
Brzosko WJ, Jankowski A

PADMA 28 in patients with chronic hepatitis B: Clinical and immunological effects

Since our first studies on the localization of the antigens (Hbs Ag, Hbc Ag) of the hepatitis B virus (HBV) there is now agreement that the inflammatory damage to the liver through chronically active hepatitis B (CAH-B) is not the direct result of the virus but of the immune reaction of the organism against viral antigens. Thus chronic inflammatory reaction observed in the liver of patients with CAH-B means that the organism is unable to eliminate the viral infection of the hepatocytes through the immune reaction. This pathogenic viewpoint on CAH-B and other forms of chronic viral hepatitis (C, D) stimulated us to stop treating patients with immune-suppressive and anti-inflammatory medication. After several years of attempting to treat patients with CAH-B with immuno-modulating compounds we came to the conclusion that the therapeutic use of the PADMA 28 herbal remedy is the most suitable means of achieving a clinical, biochemical, immunological and histological benefit. In the course of the past decade we have treated 126 adults and 52 children with CAH-B. Following a two-year treatment with PADMA 28 (daily dose: 3 x 2 tablets) the following results were achieved: About 90% of the patients had their biochemical parameters normalized and the number of the T-lymphocyte subsets (CD3, CD4, CD8, CD4/CD8) improved. In about 15% of patients viral infection was eliminated. About 70% of patients seroconverted from HBe-Ag positivity to anti-HBe. In around 10% of the patients no clinical or serological improvement was observed following the treatment. PADMA 28 was well tolerated by the patients. Their appetite and
general wellbeing improved. Ultrasonographic tests of liver and spleen gave no indication of any cirrhotic lesions.

Multiple sclerosis MS
Korwin-Piotrowska T, Nocon D, Stankowska-Chomicz A, Starkiewicz A, Wojcicki J, Samochowiec L

Experience of PADMA 28 in Multiple Sclerosis.

One hundred subjects suffering from a chronic progressive form of multiple sclerosis were randomly divided into two equal groups. Group 1 received PADMA 28, two tablets three times a day, and group 2, the control, was treated only symptomatically. Treatment and observation lasted for 1 year. Examinations performed directly prior to the study and in the course of observation included: neurological state, visual and auditory evoked potentials, basic laboratory tests. A positive effect of PADMA 28 was observed in 44% of patients with multiple sclerosis in the form of improvement of general condition, increase of muscle strength, decrease or disappearance of disorders affecting sphincters. In 41% of patients with initially an abnormal tracing of visual evoked potentials, an improvement or normalization was achieved. Of patients who did not receive PADMA 28 none felt better, moreover, 40% of them showed a deterioration. Tolerance of the drug was excellent.

Immune defence
Jankowski A, Jankowska R, Brzosko WJ

Treatment of children prone to infection with PADMA 28.

The 3 year study covered 305 children. Only those children were included who during the preceding 9 months had suffered at least one infection per month, including at least 3 times bronchitis and/or pneumonia. Three months before treatment with PADMA 28 medication with steroids was discontinued. The same applied to medication with antibiotics which was discontinued at least two weeks before medication with PADMA 28. The efficacy of the treatment was evaluated by the frequency and severity of respiratory infection during 9 months of treatment. 71.5 % of the patients showed a clear improvement in their condition.

Other studies have shown the following effects of PADMA 28 on the immune system of patients: it improves the phagocytic activities of macrophages versus bacteria and immune complexes. It can normalize the CD4/CD8 index of the T-lymphocytes. Furthermore, PADMA 28 can increase the synthesis of interferons, Interleukin-1, Interleukin-2 and the migration inhibition factor.

Cardiology

Literature

PADMA 28 in cardiology: the role of regulatory systems in inflammatory heart diseases

Cardiac death resulting from the most common inflammatory disease, namely arteriosclerosis, is still the main cause of death in the Western world. Angina pectoris, myocardial infarction or sudden cardiac death are examples of this. The great complexity of the cytokine and receptor network that is responsible for inflammatory reactions makes it difficult to treat individual processes. A possible therapy must therefore be focussed primarily on the increased regulatory capacity of the organism. A plant-based therapy has the potential to restore the efficacy of the regulatory systems. With the example of PADMA 28, Zebrowski describes a plant-based compound with such comprehensive multidirectional effects on the organism.
Dental pulpitis

Füllemann F

Padma 28 in the treatment of chronic dental pulpitis: an observational case study in 49 patients


In the case of pulpitis the dentist has to differentiate between a reversible and therefore treatable pulpal inflammation and an irreversible damage of the pulpa, according to the clinical symptoms. From these one cannot draw conclusions about the effective histological condition of the pulpa. Early stages of pulpitis cannot be recognized by X-ray either. Objectives: By means of case studies in the course of daily dental practice the following questions are addressed: Is dental pulpitis an indication for the use of the Tibetan remedy Padma 28? Can a root canal treatment be prevented by administering Padma 28? What dosage is appropriate in this indication? Patients and Methods: 53 patients with symptoms of chronic dental pulpitis but without clear indication for an immediate root canal treatment were prescribed 2 × 2 tablets Padma 28 daily, for 15 days. 49 patients took the preparation, and the course of symptoms was recorded and analyzed according to a simple scheme. Results: 27 of these patients (55%) were free of pain within 1 month. A total of 40 patients (81%) reached a pain-free state after a longer period. By now, in most cases observations have been made for a period of 2–3 years (maximum: 5.5 years). 12 patients (24%) remained without relapse so far for more than 3 years. These experiences allow to deduce possible indications and clinical symptoms for the use of Padma 28. Conclusions: These results encourage the use of Padma 28 as a complementary preparation with little side effects, in unclear cases of pulpitis. The clinical development can be observed without further treatment if the patient does not need pain medication. Most patients (>80%) showed a complete remission, positively affected and expedited by Padma 28; root canal treatments or extractions could be prevented. In many cases the improvement has sustained over observation periods of >3 years. Criteria for therapeutic decisions are proposed.

Clinical experiences

Bommeli C, Bohnsack R, Kolb C

Clinical experiences in the general practice with a multicompound preparation derived from Tibetan medicine


A total of 147 retrospective practical-experience reports from 15 Swiss doctors on treatment with the multi-substance preparation PADMA 28 were collected and evaluated. In an average of 60% of the cases the product was used successfully in the treatment of circulatory disorders in everyday general practice. Together with the treatment of cardiovascular diseases and cerebral circulatory disorders, arteriosclerotic diseases thus constitute the main field of application (75%). These indications include memory problems, tinnitus and visual disorders. In general practice, other chronic inflammatory conditions such as back ailments and joint pain, as well as dizziness, asthenia, weariness, respiratory disorders, phlebitis and allergies are further indications for the product (25%). The efficacy was assessed largely as good (75%) by both the doctors and the patients. The good assessment of the tolerability (94% of the doctors and 85% of the patients) and the drug form (82%) is reflected in the good compliance (87%). About one-quarter of all the patients were treated only with PADMA 28. The good results of the monotherapy with the Tibetan remedy of initial symptoms of peripheral circulatory disorders are of particular significance for the prevention and treatment of arteriosclerotic disease.
**Review**

Anonymous

**Arteriosclerosis, restenosis and tumor progression: PADMA 28 has antiproliferative effects on activated smooth-muscle cells and tumor cells.**

The proliferation of smooth-muscle cells (SMC) of the wall of the arteries plays an important role in the development of atherosclerosis and restenosis following angioplasty and in the development of tumor progression. PADMA 28 extract inhibits the proliferation of unstimulated SMCs as well as of cells stimulated with basic fibroblast growth factor (bFGF) and/or thrombin, in vitro. The antiproliferative effect of PADMA 28 was also demonstrated in activated tumor-cell cultures and was reversible after removal of the product, which indicates that the antiproliferative effect is not the result of cell damage. PADMA 28 can therefore be used prophylactically as an anti-arteriosclerosis agent, e.g. to prevent hyperplasia of the tunica intima and postoperative stenosis; it could also play a role in the prevention and treatment of other vascular diseases and of tumor growth and metastases.

---

**Inflammaging**

Ginsburg I, Vennos C, Koren E

**Inflammaging - Aging as a Consequence of Chronic Inflammation: The Example of Padma 28**


[Article in German, Abstract in English available]

**Inflammaging** describes a chronic, systemic inflammatory state that results from age-related changes of the immune system. It is thought to be the basis of various chronic inflammatory diseases of old age, e.g. atherosclerosis, diabetes mellitus type 2, as well as Alzheimer's disease and cancer. The development of this proinflammatory milieu and its progression is accelerated and in some cases aggravated by oxidative stress. Complex phytotherapeutics (such as Padma 28) act as pleiotropic compounds, suited to stop these pathogenic processes at different sites of action. Besides the clinical effect of Padma 28, different mechanisms of action of the preparation in atherosclerosis are well documented and research results support the hypothesis that a multi-target approach with herbal multicomponds may offer a valuable contribution to new prevention and treatment strategies in chronic inflammatory conditions. Herbal multicomponds are therefore well suited to positively influence „inflammaging“ conditions and to slow down the development of ensuing diseases, in some cases also preventing them.

Schwabl H, Vennos C.

**Chronic Inflammation and Extracellular Matrix ECM: Starting Point for an Anti-Inflammatory Intervention Scheme**


**Background:** In inflammation a signal cascade is set in motion, which sustains itself via positive feedback mechanisms. If in spite of the elimination of the underlying cause of the inflammation these feedback loops can not be interrupted, the inflammation becomes chronic. Chronic inflammations stop being a part of the normal healing process. As a discrete aspect of pathogenesis they often harm the body tissue more than the initial cause of inflammation. The complex inflammatory processes encompass more than the interaction of cellular protagonists and their cytokines. With the system of the ground regulation complementary medicine offers an expanded functional space, in which immune cells and mesenchymal cells interact with the extracellular matrix, the structured interstitium, as well as the capillary blood system, nerve endings and lymph vessels. **Objective and method:** The immunologic view of the inflammatory reaction is compared to the system of the ground regulation according to A. Pischinger and H. Heine. The question is analysed, wether from this comparison new integrative approaches result regarding an anti-inflammatory therapy as well as prevention and aftertreatment of chronic inflammatory diseases. **Results:** Not only different anti-inflammatory molecules are necessary for termination of inflammatory reactions, especially in chronic inflammations the regeneration of the regulatory capacity of the system of ground regulation is essential. Only triggering and amplifying anti-inflammatory impulses initiate the actual healing phase. From this concept a three-step intervention schema can be derived, which is focused on the extracellular matrix: through the three phases of therapy, “reload-protect-trigger”, different functions of
The extracellular matrix can be addressed. By means of examples this integrative concept is explained and transferred into a schema applicable in practice. This allows the easy assessment of the relevance of individual treatments to the three-step functional model of the extracellular matrix in everyday life. The integrative point of view seems necessary insofar as especially in the area of chronic inflammations a multitude of methods are applied but an overall therapy concept is often missing.

**Tibetan medicine in Europe**

Schwabl H, Vennos C

The “multi-target” approach of Tibetan remedies - Mechanisms of action of Padma 28 in inflammation, with the example of atherosclerosis


Chronic inflammation poses high demands on modern medicine. Multifactorial chronic diseases require multilevel therapies that work on different pathogenic processes and at the same time have few side effects. Due to their multicomponent composition and their high tolerability Tibetan medicines offer valuable therapeutic approaches. Tibetan formulas are multicomponents containing different, mostly herbal raw material. Their composition is based on the principles of Tibetan medicine. Therapeutically cooling or warming formulas are used to counterbalance the disturbed equilibrium of bodily energies. Because of the complex pharmacological activity profile of Tibetan remedies they act as “multi-target drugs”. The concept of multi-target drugs comprises partial effects at multiple sites of action simultaneously. Such a profile of activity is not limited to a strong effect at only one site of action as it occurs in the case of single-target drugs. This multi-target approach seems especially appropriate in multifactorial, chronic diseases.

The multicomponent formula Padma 28 is based on Tibetan medicine. In clinical, in-vitro und ex-vivo studies it showed promising effects on atherosclerotic changes. The comparison of these scientific results and the processes in atherogenesis clearly proves the character of Padma 28 as a multi-target drug. The multicomponent interacts with the pathogenic processes simultaneously at different sites of the artery wall and in different stages of the disease. The example of Padma 28 in atherosclerotic changes shows that Tibetan medicines act as multi-target drugs and offer promising therapeutic approaches, especially in chronic diseases with complex etiology. The subject of multi-target drugs represents an important contribution to the modern understanding of Tibetan medicines and complementary practice in general.

**In vitro studies**


Anti-inflammatory mechanisms of the Tibetan herbal preparation Padma 28 in the vessel wall


The Tibetan herbal preparation Padma 28 has been shown to act as an anti-atherosclerotic agent in advanced peripheral arterial occlusive disease. We tested the effect of aqueous Padma 28 extracts on both the C-reactive protein (CRP) induced expression of the pro-inflammatory cell adhesion molecule E-selectin and the anti-atherosclerotic protective enzyme heme oxygenase-1 (HO-1) in human aortic endothelial cells. Methods and Results: According to FACS analysis, quantitative RT-PCR and Western blot, CRP-induced E-selectin expression was completely prevented by aqueous Padma 28 extracts. Additionally, Padma 28 mediated an up to 60-fold upregulation of HO-1 mRNA as measured by quantitative RT-PCR. This upregulation could also be demonstrated on the protein level. Conclusion: Aqueous extracts of the Tibetan herbal preparation Padma 28 inhibit CRP-induced expression of the inflammatory cell adhesion molecule E-selectin and lead to upregulation of the vascular protective enzyme HO-1 in human aortic endothelial cells. These properties may be responsible for its antiatherosclerotic effects in peripheral arterial occlusive disease.

Barak V, Kalickman I, Halperin T, Birkenfeld S, Ginsburg I

PADMA 28, A Tibetan herbal preparation is an inhibitor of inflammatory cytokine production.
Background: Previous studies have shown that PADMA 28, a multicomponent, traditional Tibetan herbal plant preparation possesses a variety of beneficial effects on several experimental models of inflammatory and immune processes, including autoimmune diabetes and autoimmune encephalomyelitis. In humans, PADMA 28 attenuated the symptoms associated with intermittent claudications in atherosclerotic patients. Objective: To assess the effect of PADMA 28 on the immune system, e.g. cytokine (interleukins) production. Design: Cytokine production by human blood monocytes (derived from 12 healthy donors) stimulated in vitro, either by endotoxin (LPS) from Salmonella typhi or by lipoteichoic acid (LTA) from group A Streptococci was modulated by PADMA-28. Results: The present study showed that an aqueous extract of PADMA 28 strongly decreased the production of the inflammatory cytokines IL-1β, IL-6, IL-8 and TNF-α, and more moderately, also decreased the anti-inflammatory cytokine IL-10 induced by LPS. However, the LTA – induced IL-10 production was [not significantly] increased by the low dose PADMA 28, while not effected at all by the higher dose of PADMA 28. Conclusions: The data from these finding suggest a possible clinical efficacy of PADMA 28 either in autoimmune and in inflammatory conditions or in post-inflammatory sequelae, as previously shown in vivo and human studies, probably by decreasing inflammatory cytokines.
PADMA 28 *

LITERATURVERZEICHNIS 09 / 2010
SCIENTIFIC DOCUMENTATION
DOCUMENTATION SCIENTIFIQUE

Dieser Index ist medizinischen Fachpersonen vorbehalten.
This index is exclusively for medical professionals.
Cet index est exclusivement pour du personnel médical.

Neu in dieser Ausgabe, new in this edition, nouveaux dans cette édition:

- von Muralt Portmann
  Parästhesien bei Diabetes mellitus - Therapieansätze mit PADMA 28

- Melzer J, Saller R
  Das tibetische Kombinationspräparat Padma 28 bei peripherer arterieller Verschlusskrankheit.
  Internist Prax. 2010;2:403-7................................................................................ 3

- Eitner A
  Tibetische Medizin in Europa und Asien - Herausforderungen und Chancen
  Schweiz Zschr GanzheitsMedizin. 2010;22:24-6..................................................... 8

- Anonymous
  Arteriosklerose, Restenose und Tumorprogression: PADMA 28 wirkt antiproliferativ auf aktivierte glatte Muskelzellen und Tumorzellen.
  Schweiz Zschr GanzheitsMedizin. 2009;21(5):232-4.............................................. 8

- Vennos C, Schwabl H, Kull HU
  Padma 28 bei Durchblutungsstörungen.
  Hausarzt Praxis. 2010;10:40-1.................................................................................. 3

* PADMED CIRCOSAN ist identisch mit PADMA 28. Es steht in der Schweiz speziell dem Arzt zur Verfügung und ist kassenzulässig.

* PADMED CIRCOSAN is identical to PADMA 28. It is available in Switzerland especially for doctors and is reimbursed by the health insurances.

* PADMED CIRCOSAN est spécialement à la disposition des médecins en Suisse. Il est identique à PADMA 28 et remboursé par la caisse maladie.
<table>
<thead>
<tr>
<th>A Praxisthemen</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Arteriosklerose</td>
<td>3</td>
</tr>
<tr>
<td>2. Hepatitis und Lebererkrankungen</td>
<td>5</td>
</tr>
<tr>
<td>3. Rheuma toide Arthritis</td>
<td>5</td>
</tr>
<tr>
<td>4. Multiple Sklerose</td>
<td>6</td>
</tr>
<tr>
<td>5. Infektionen, Atemwege</td>
<td>6</td>
</tr>
<tr>
<td>6. Andere Einsatzgebiete</td>
<td>7</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>B Theoretische Arbeiten</th>
<th>8</th>
</tr>
</thead>
<tbody>
<tr>
<td>7. Übersichtsarbeiten</td>
<td>8</td>
</tr>
<tr>
<td>8. In vitro Resultate</td>
<td>10</td>
</tr>
<tr>
<td>9. Informationen zum Produkt</td>
<td>13</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>C Kongresse</th>
<th>13</th>
</tr>
</thead>
<tbody>
<tr>
<td>Die Publikationen sind in jenen Sprachen erhältlich, in denen der Titel aufgelistet ist.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>A Practical Topics</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Atherosclerosis</td>
<td>3</td>
</tr>
<tr>
<td>2. Hepatitis and liver disease</td>
<td>5</td>
</tr>
<tr>
<td>3. Rheumatoid arthritis</td>
<td>5</td>
</tr>
<tr>
<td>4. Multiple sclerosis</td>
<td>6</td>
</tr>
<tr>
<td>5. Infections, respiratory tract</td>
<td>6</td>
</tr>
<tr>
<td>6. Other fields of application</td>
<td>7</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>B Theoretical Publications</th>
<th>8</th>
</tr>
</thead>
<tbody>
<tr>
<td>7. Reviews</td>
<td>8</td>
</tr>
<tr>
<td>8. In vitro results</td>
<td>10</td>
</tr>
<tr>
<td>9. Product information</td>
<td>13</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>C Congresses</th>
<th>13</th>
</tr>
</thead>
<tbody>
<tr>
<td>The publications are available in the languages in which the titles are listed.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>A Thèmes Pratiques</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Artériosclérose</td>
<td>3</td>
</tr>
<tr>
<td>2. Hépatite et maladies du foie</td>
<td>5</td>
</tr>
<tr>
<td>3. Polyarthrite rhumatoïde</td>
<td>5</td>
</tr>
<tr>
<td>4. Sclérose en plaques</td>
<td>6</td>
</tr>
<tr>
<td>5. Infections, voies respiratoires</td>
<td>6</td>
</tr>
<tr>
<td>6. Autres domaines d’intervention</td>
<td>7</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>B Publications Théoriques</th>
<th>8</th>
</tr>
</thead>
<tbody>
<tr>
<td>7. Articles de revue</td>
<td>8</td>
</tr>
<tr>
<td>8. Résultats in vitro</td>
<td>10</td>
</tr>
<tr>
<td>9. Informations sur le produit</td>
<td>13</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>C Congrès</th>
<th>13</th>
</tr>
</thead>
<tbody>
<tr>
<td>Les publications sont disponibles dans les langues dans lesquelles le titre est écrit.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>C Clinical trials, case reports</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>R Overviews, reviews</td>
<td>5</td>
</tr>
<tr>
<td>S In vitro/ex vivo study</td>
<td>6</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>C Klinische Studien, Fallberichte</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>R Übersichtsarbeiten, Zusammenfassungen</td>
<td>5</td>
</tr>
<tr>
<td>S In vitro/ex vivo Studie</td>
<td>6</td>
</tr>
</tbody>
</table>
### A Praxisthemen / Practical topics / Thèmes pratiques

#### 1. Arteriosklerose / Atherosclerosis / Arteriosclérose

<table>
<thead>
<tr>
<th>Reference</th>
<th>Title</th>
</tr>
</thead>
</table>
| R | Melzer J, Saller R  
Das tibetische Kombinationspräparat Padma 28 bei peripherer arterieller Verschlusskrankheit.  
| R | Vennos C, Schwabl H, Kull HU  
Padma 28 bei Durchblutungsstörungen.  
| C R | Hausmann B  
PAVK-Management in der Praxis - Behandlung von PAVK mit Padma 28  
Schweiz Zschr GanzheitsMedizin 2008; 20:258. |
| R | Gröchenig E  
Behandlung der Claudicatio intermittens mit Padma 28  
| R | Allemann D  
Cerebraler Insult: Prävention, Verlauf und Prognose - Welchen Einfluss hat das Tibetische Arzneimittel Padma 28?  
| C R | Melzer J, Brignoli R, Diehm C, Reichling J, Do DD, Saller R  
Treating intermittent claudication with Tibetan medicine Padma 28: Does it work?  
| R | Melzer J, Brignoli R, Saller R  
Wirksamkeit und Sicherheit von Padma 28 bei peripherer arterieller Verschlusskrankheit  
[Efficacy and Safety of Padma 28 in Peripheral Arterial Occlusive Disease. Article in German, English abstract available]  
| R | Schwabl H  
Tibetische Medizin bei atherosklerotischen Beschwerden  
[Tibetan medicine in atherosclerotic disorders. Article in German, English abstract available]  
Dt Ztschr Akup 2006;Suppl 2:132-5. |
| R | Pittler MH, Ernst E  
Complementary therapies for peripheral arterial disease: systematic review  
C Feldhaus S
Ganzheitliches Therapiekonzept bei pAVK

C Panjwani HK, Brzosko WJ
Influence of selected immunocorrecting drugs on intellectual function of the brain
due to arteriosclerosis
Nowiny Lekarskie (Medical News) 1998;5:665-70.

The efficacy of PADMA 28, a herbal preparation, in the treatment of intermittent
claudication: a controlled double-blind pilot study with objective assessment of
chronic occlusive arterial disease patients

C Smulski HS, Wojcicki J
Placebo-controlled, double-blind trial to determine the efficacy of the Tibetan plant
preparation PADMA 28 for intermittent claudication
[Plazebokontrollierte Doppelblindstudie zur Wirkung des tibetischen Kräuterpräparates
PADMA 28 auf die Claudicatio intermittens]

C Mehlsen J, Drabaek H, Peterson JR, Winther K
Der Effekt einer tibetischen Kräutermischung (PADMA 28) auf die Gehstrecke bei
stabler Claudicatio intermittens

C Drabaek H, Mehlsen J, Himmelstrup H, Winther K
A botanical compound, PADMA 28, increases walking distance in stable intermittent
claudication

C Wojcicki J, Samochowiec L
Controlled double-blind study of PADMA 28 in angina pectoris
[Kontrollierte Doppelblind-Studie von PADMA 28 bei Angina Pectoris]

C Schräder R, Nachbur B, Mahler F
Die Wirkung des tibetanischen Kräuterpräparates Padma 28 auf die Claudicatio
intermittens
2. Hepatitis und Lebererkrankungen / Hepatitis and liver disease / Hépatite et maladies du foie

**C**

Hryniewiecki L, Brzosko WJ, Klincewicz H, Stachowiak Cz

*Treatment of patients with active liver cirrhosis with PADMA 28*


**C**

Gladysz A, Juszczyk J, Brzosko WJ

*Influence of PADMA 28 on patients with chronic active hepatitis B*

Phytother Res 1993;7:244-7.

**C**

Brzosko WJ, Jankowski A

*PADMA 28 bei chronischer Hepatitis B: Klinische und immunologische Wirkungen*  
[PADMA 28 in patients with chronic hepatitis B: Clinical and immunological effects]  
[PADMA 28 dans l'hépatite B chronique: effets cliniques et immunologiques]


**C**

Brzosko WJ, Gladysz A, Juszczyk J

*PADMA 28 in der Behandlung der chronisch aktiven Hepatitis*  
[PADMA 28 in the treatment of chronic active hepatitis]


3. Rheumatoide Arthritis / Rheumatoid arthritis / Polyarthrite rhumatoïde

**C**

Bernacka K, Sierakowski St, Brzosko WJ

*PADMA 28 in the therapy of rheumatoid arthritis. A 6-month clinical and laboratory study*


**C**

Brzosko WJ, Jankowski A, Prusek W, Ollendiek H

*Influence of PADMA 28 and thymus extract on clinical and laboratory parameters of children with juvenile chronic arthritis*

4. Multiple Sklerose / Multiple sclerosis / Sclérose en plaques

R Bowling AC, Stewart TM
*Current complementary and alternative therapies for multiple sclerosis*

R Siehe auch / See also / à voir aussi:
[no authors listed]
*Multiple Sklerose: Komplementär-medizinische und alternative Therapien*
[Multiple Sclerosis: Complementary-medicine and alternative therapies.]

C Korwin-Piotrowska T, Nocon D, Stankowska-Chomicz A, Starkiewicz A, Wojcicki J, Samochowiec L
*Experience of PADMA 28 in Multiple Sclerosis*

5. Infektionen, Atemwege / Infections, respiratory tract / Infections, voies respiratoires

C Jankowski A, Jankowska R, Brzosko WJ
*Behandlung infektanfälliger Kinder mit PADMA 28*
[Treatment of children prone to infection with PADMA 28]
[Traitement d'enfants sujets aux infections par PADMA 28]

C Jankowski S, Jankowski A, Zielinska S, Walczuk M, Brzosko WJ
*Influence of PADMA 28 on the spontaneous bactericidal activity of blood serum in children suffering from recurrent infections of the respiratory tract*

C Jankowski A, Drabik E, Szysko Z, Stasiewin W, Brzosko WJ
*Die Behandlung rezidivierender Atemwegsinfektionen bei Kindern durch Aktivierung des Immunsystems*
[Treatment with PADMA 28 of children with recurrent infections of the respiratory tract]
[Le traitement d'infections récidivantes des voies respiratoires chez les enfants - par immunoactivation]
6. Andere Einsatzgebiete / Other fields of application / Autres domaines d’intervention

C
von Muralt Portmann
Parästhesien bei Diabetes mellitus - Therapieansätze mit PADMA 28

RC
Röösli MB
Systematische Übersichtsarbeit: Klinische Studien zur Wirksamkeit und Sicherheit des phytotherapeutischen Kombinationspräparats PADMA 28
Dissertation Universität Zürich 2009

R
Anonymous
PADMA 28 in der Kardiologie: Die Rolle regulierender Systeme bei entzündlichen Herzkrankheiten

C
Kappler S
Systemisch limitierte Sklerodermie - Therapieoption mit Padma 28 in einem klinisch fortgeschrittenen Stadium

C
Füllemann F
Padma 28 in der Behandlung von chronischen Zahnpulpitiden: Eine Praxisbeobachtung an 49 Fällen
[Padma 28 in the treatment of chronic dental pulpitis: an observational case study in 49 patients]

C S
Brunner-La Rocca HP, Schindler R, Schlumpf M, Saller R, Suter M
Effects of the Tibetan herbal preparation PADMA 28 on blood lipids and lipid oxidisability in subjects with mild hypercholesterolaemia

C
Günsche M
Therapieresistenz bei Tagesmüdigkeit, Antriebsschwäche und Konzentrationsstörung - Erfolgreiche Behandlung mit PADMA 28

C
Rüttgers JO
Crux medicorum: Das offene Bein - Langzeittherapie des chronischen Ulcus cruris venosum mit PADMA 28 und Lymphdrainage
[Crux medicorum: Ulcerated leg - Long-term treatment of chronic Ulcus cruris venosum with PADMA 28 and lymph drainage]
R Zebrowski MR

Die Rolle regulierender Systeme bei entzündlichen Herzkrankheiten
[The role of regulatory systems in inflammatory heart disease]

C R Bommeli C, Bohnsack R, Kolb C

Praxiserfahrungen mit einem Vielstoffpräparat aus der tibetischen Heilkunde
[Practical experiences with a multi-compound preparation from Tibetan Medicine PADMA 28]

B Theoretische Arbeiten / Theoretical Publications / Publications Théoriques

7. Übersichtsarbeiten / Reviews / Articles de revue

Interview

Eitner A

Tibetische Medizin in Europa und Asien - Herausforderungen und Chancen

Anonymous

Arteriosklerose, Restenose und Tumorprogression: PADMA 28 wirkt antiproliferativ auf aktivierte glatte Muskelzellen und Tumorzellen.

Vennos C, Schwabl A, McHugh E, Schwabl H

A structured process of translation and integration of traditional Asian herbal formulas in the European context: Experience from 40 years

Hausmann B

Inflammaging in der Praxis

Ginsburg I, Vennos C, Koren E

Inflammaging - Altern als Konsequenz chronischer Entzündungen: Das Beispiel Padma 28
[Inflammaging - Aging as a Consequence of Chronic Inflammation: The Example of Padma 28. Article in German, Abstract in English available]
[L'Inflammaging – Le vieillissement induit par les inflammations chroniques : L'exemple de Padma 28. Article en allemand, résumé en français]
Schwabl H, Vennos C  
**Systems biology - Herausforderung und Anregung für die Komplementärmedizin**  
[System Biology - Challenges and Suggestions for Complementary Medicine. Article in German, abstract in English available]  

Brockes MC, Schmidt S, Buser J, Baumann D  
**E-Health: Medizinische Online-Beratung plus im UniversitätsSpital Zürich**  
[E-Health: Medical Online Advice at the University Hospital Zurich. Article in German, Abstract in English available]  

Schwabl H, Vennos C  
**Chronische Entzündung und Extrazelluläre Matrix ECM: Ausgangspunkt für ein anti-inflammatorisches Interventionsschema**  
Schweiz Zschr GanzheitsMedizin 2007,19(5):269-76

Schwabl H.  
**Scientific and Regulatory Challenges for Tibetan Herbal Formulas in Europe**  

Vennos C, Schwabl H  
**Chronische Low-Level Entzündungen: Pflanzliche Vielstoffgemische als integrative Erweiterung antioxidativer Strategien**  

Schwabl H, Vennos C  
**Der „multi-target“-Ansatz Tibetischer Heilmittel - Wirkmechanismen von Padma 28 im entzündlichen Geschehen am Beispiel der Arteriosklerose**  
[The „multi-target“ approach of Tibetan remedies - Mechanisms of action of Padma 28 in inflammation, with the example of atherosclerosis]  

Gyatso T, 14th Dalai Lama  
**The contribution of the Tibetan medical system to global health**  
Forsch Komplementärmed 2006;13(Suppl 1):VI.

Saller R  
**Tibetische Heilmittel bei chronischen Erkrankungen**  
Forsch Komplementärmed 2006;13(Suppl 1):VII-VIII.

Schwabl H, Geistlich S, McHugh E  
**Tibetische Arzneimittel in Europa: Historische, praktische und regulatorische Aspekte**  
[Tibetan Medicines in Europe: Historical, Practical and Regulatory Aspects. Article in German, abstract available in English]  
Gestörte Glukosehomöostase - Möglichkeiten der Prävention in einem multifaktoriellen Geschehen
Schweiz Zschr GanzheitsMedizin 2006;18(5):244-5.

Vennos C, Schwabl H
Tibetische Medizin - Vielstoffgemische in der modernen Forschung

Schwabl H, Vennos C
Tibetische Medizin - Grundzüge einer erweiterten Phytotherapie

8. In vitro Resultate / In vitro results / In vitro résultats

Anti-inflammatory mechanisms of the Tibetan herbal preparation Padma 28 in the vessel wall
[Forsch Komplementärmed 2006;13(Suppl 1):13-7.]

Überall F, Fuchs D, Vennos C
Das anti-inflammatorische Potential von Padma 28 - Übersicht experimenteller Daten zur antiatherogenen Wirkung und Diskussion des Vielstoffkonzepts
[Forsch Komplementärmed 2006;13(Suppl 1):7-12.]

Siehe auch / See also / à voir aussi:
Combé M
Arteriosklerose - ein komplexes Geschehen: In-vivo-Studie zur ganzheitlichen Wirkung von Padma 28

Jenny M, Schweiger W, Bernhard D, Wruilich OA, Cosaceanu D, Fuchs D, Überall F
Apoptosis induced by the Tibetan herbal remedy PADMA 28 in the T cell-derived lymphocytic leukaemia cell line CEM-C7H2

Siehe auch / See also / à voir aussi:
Class C
Pflanzliches Vielstoffgemisch unterstützt synthetische Krebstherapie: Padma 28 induziert in der von T-Zellen abgeleiteten lymphozytischen Leukämie (Zell-Linie CEM-C7H2) eine Apoptose
PADMA 28: A multi-component herbal preparation with retinoid-like dermal activity but without epidermal effects

PADMA-28, a traditional Tibetan herbal preparation, blocks cellular responses to bFGF and IGF-I

S Ginsburg I, Sadovnic M, Oron M, Kohen R
Novel chemiluminescence-inducing cocktails, part II: Measurement of the antioxidant capacity of vitamins, thiols, body fluids, alcoholic beverages and edible oils

S Barak V, Kalickman I, Halperin T, Birkenfeld S, Ginsburg I
PADMA 28, A Tibetan herbal preparation is an inhibitor of inflammatory cytokine production

S Neurauter G, Wirleitner B, Schroecksnadel K, Schennach H, Ueberall F, Fuchs D
PADMA 28 modulates interferon-γ-induced tryptophan degradation and neopterin production in human PBMC in vitro

R Siehe auch / See also / à voir aussi:
Ueberall F, Fuchs D
Chronische Entzündungen: Modulation des Zytokinnetzwerkes durch PADMA 28
[Chronic inflammation: Modulation of the cytokine network by PADMA 28]

S Weseler A, Saller R, Reichling J
Comparative Investigation of the Antimicrobial Activity of PADMA 28 and Selected European Herbal Drugs

R Stampfli S, Bommeli C, Schwabl H
Zum antioxidativen und antiinflammatorischen Wirkprofil von PADMA 28
[The antioxidative and anti-inflammatory properties of PADMA 28]
[A propos du profil d’action anti-oxydant et anti-inflammatoire de PADMA 28]
Moeslinger T, Friedl R, Volf I, Brunner M, Koller E, Spieckermann PG

Inhibition of inducible nitric oxide synthesis by the herbal preparation PADMA 28 in macrophage cell line

[L'inhibition de la synthèse inductible du monoxyde d'azote par la préparation végétale PADMA 28 dans une ligne des cellules macrophage. Article en anglais, résumé en français]


Suter M, Richter C

Anti- and pro-oxidative properties of PADMA 28, a Tibetan herbal formulation


PADMA-28, a traditional Tibetan herbal preparation inhibits the respiratory burst in human neutrophils, the killing of epithelial cells by mixtures of oxidants and pro-inflammatory agonists and peroxidation of lipids


Matzner Y, Sallon S

The effect of PADMA-28, a traditional Tibetan herbal preparation, on human neutrophil function


Winther K, Kharazmi A, Himmelstrup H, Drabaek H, Mehlsen J

PADMA-28, a botanical compound, decreases the oxidative burst reaction of monocytes and improves fibrinolysis in patients with stable intermittent claudication


Samochowiec J, Palacz A, Bobnis W, Lisiecka B

Oscillating potentials of the electroretinogram in the evaluation of the effects of PADMA 28 on lipid metabolism and vascular changes in humans


Altermatt R, von Felten A

In-Vitro-Untersuchungen mit PADMA 28: Hemmung der Thrombozytenfunktion

[In vitro tests with PADMA 28: Inhibition of platelet function]

9. Informationen zum Produkt / Product information / Informations sur le produit

S Bui M
Rapport d’expertise – Vitamine K dans Padma 28
[Expertenbericht - Vitamin K in Padma 28]
[Expert’s report - Vitamin K in Padma 28]
Swiss Institute of Vitamins, Epalinges / Switzerland, 1999; Dec 16:1-2.

S Isliker H
Rapport d’expertise - Vitamines dans Padma 28
[Expertenbericht - Vitamine in Padma 28]
[Expert’s report – Vitamins in Padma 28]

C Kongresse / Congresses / Congrès

R Falch B
Störung der Mikrozirkulation: Phytotherapie zur Prophylaxe und Behandlung
22. Tagung der SMGP - Schweizerische Medizinische Gesellschaft für Phytotherapie,

R no authors listed
Tibetische Heilmittel bei chronischen Erkrankungen - Medizinisch-wissenschaftlicher
Kongress, Universität Zürich/ Völkerkundemuseum, 3. November 2005

R Congress
Anti-inflammatory strategies in phytotherapy by the example of Tibetan medicine -
Discussion on phytotherapy in Lucerne 2003 at the hospital of Lucerne, abstracts of
Pospischil A
[PADMA 28: Ein Kräuterpräparat aus der Tibetischen Medizin im Fokus der Wissenschaft.
"Antientzündliche Strategien in der Phytotherapie"]
[PADMA 28: une préparation à base d’herbes issue de la médecine tibétaine focalise
l’intérêt des scientifique. "Stratégies anti-inflammatoires en phytothérapie"]